Back to journals
Academic Journal

Biomedicine & Pharmacotherapy

4 Papers Indexed in Blossom

Published Papers

Open Accessindividual

Population pharmacokinetic-pharmacodynamic modeling of co-administered N,N-dimethyltryptamine and harmine in healthy subjects

This secondary of a single-blind, randomised study (n=16) using DMT (0-120mg) with harmine (0-180mg) in an ayahuasca-inspired (‘pharmahuasca’) formulation found that harmine significantly enhanced DMT bioavailability and prolonged absorption, resulting in higher sustained plasma concentrations and increased subjective psychedelic effects, with population pharmacokinetic/pharmacodynamic modeling revealing substantial interindividual variability in clearance, bioavailability, and sensitivity to psychedelic effects.

Published
Journal
Biomedicine & Pharmacotherapy
Authors
Äbelö, A., Smallridge, J. W., Von Rotz, R., Dornbierer, D. A., Egger, K., Ashton, M., Scheidegger, M.
Open Accessindividual

Examining the pharmacokinetic and pharmacodynamic interaction of N,N-dimethyltryptamine and harmine in healthy volunteers: Α factorial dose-escalation study

This single-blind, randomised, two-arm, factorial, dose-finding study (n=16) investigates the pharmacokinetic and pharmacodynamic interactions between DMT and harmine in an ayahuasca-inspired ('pharmahuasca') formulation. Participants received six dose combinations (0-120 mg DMT, 0-180 mg harmine) via a transmucosal delivery system. Results show dose-dependent subjective effects lasting 4-5 hours, with peak plasma levels (Cmax) of 33 ng/mL for DMT and 49 ng/mL for harmine. Harmine increased DMT bioavailability and plasma half-life while altering its metabolism. The formulation demonstrated a favourable safety profile, supporting its potential for further clinical testing in affective disorders.

Published
Journal
Biomedicine & Pharmacotherapy
Authors
Egger, K., Redondo, J. J., Müller, J., Dornbierer, J., Smallridge, J., Aicher, H. D., Meling, D., Kost, J., Puchkov, M., Äbelö, A., Seifritz, E., Quednow, B. B., Von Rotz, R., Scheidegger, M., Dornbierer, D. A.
Paywallindividual

Metabolomics and integrated network analysis reveal roles of endocannabinoids and large neutral amino acid balance in the ayahuasca experience

This study (n=23) assessed the human metabolomics signature after consumption of ayahuasca and its connection with both the psychedelic-induced subjective effects and the plasma concentrations of ayahuasca alkaloids. Compared to baseline, the consumption of ayahuasca increased N-acyl-ethanolamine endocannabinoids, decreased 2-acyl-glycerol endocannabinoids, and altered several large-neutral amino acids (LNAAs). Enrichment analysis confirmed dysregulation in several pathways involved in neurotransmission such as serotonin and dopamine synthesis.

Published
Journal
Biomedicine & Pharmacotherapy
Authors
Madrid-Gambin, F., Gomez-Gomez, A., Busquets-Garcia, A., Haro, N., Marco, S., Mason, N. L., Reckweg, J. T., Mallaroni, P., Kloft, L., Van Oorsouw, K., Toennes, S. W., De La Torre, R., Ramaekers, J. G., Pozo, O. J.
Open Accessmeta

A retrospective analysis of the “Neverending Trip” after administration of a potent full agonist of 5-HT2A receptor - 25I-NBOMe

This retrospective analysis (2022) analysed 58 reports of adverse reactions caused by 25I-NBOMe (an uncommonly used psychedelic) to identify factors that may increase the risk of hallucinogen persisting perception disorder (HPPD) following its use. In 15 reports, symptoms persisted months after HPPD use the most common of which were: pseudohallucinations, bizarre delusions and derealization. Additionally, 25I-NBOMe induced HPPD can last from 2 months up to 2 years in some cases.

Published
Journal
Biomedicine & Pharmacotherapy
Authors
Schetz, D., Schetz, A., Kocić, I.

Quick Facts

Papers Indexed
4
h-Index
169
Publisher
Elsevier
Website
Visit